StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NXG.V$0.43+2.38%
Fair $0.43+0.0%

NXG.V

NexgenRx Inc.

Healthcare / Health Information ServicesTSXV

$0.43

+0.01 (+2.38%)

Fairly Valued+0.0%Fair Value $0.43Fund rank 28/100 · Data gapFallback financials|
SA 70/B
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $1.0M · quality 52.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 32/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

70/100

B

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · NXG.VLocal privado en este navegador · NexgenRx Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$31M

P/E

21.5x

↑

EV/EBITDA

9.0x

↓

ROE

16.9%

↑

Gross Margin

83.3%

↑

Debt/Equity

0.05

↓
52-Week Range$0
$0$0

TradingView lightweight chart

NXG.V price, volumen y niveles de valoración

Último $0.430Periodo +48.3%
Fair value: $0.430

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+11.9%

FCF CAGR

+102.3%

FCF margin

25.8%

FCF / Net income

3.59x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $17.9M · net income $1.3M · FCF $4.6M

2022-FY → 2025-FY

Gross margin

83.3%+3.6% pts

Operating margin

12.5%+10.2% pts

Net margin

7.2%+7.4% pts

FCF margin

25.8%+21.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$17.9M$17.9M$16.5M$13.8M$12.8M
Net Income$1.3M$1.3M$614569.00$-331970.00$-22401.00
EBITDA$3.2M$3.2M$2.3M$1.0M$1.6M
EPS0.010.010.01-0.01-0.00
Gross Margin83.3%83.3%79.6%78.1%79.7%
Operating Margin12.5%12.5%7.3%-1.0%2.3%
Net Margin7.2%7.2%3.7%-2.4%-0.2%
Balance Sheet
Debt/Equity0.050.050.070.060.05
Current Ratio1.161.16———
Cash Flow
Free Cash Flow$4.6M$4.6M$832510.00$1.0M$559446.00
Returns
ROE16.9%16.9%8.1%-4.3%-0.3%
Valuation
P/E21.5021.5056.00——
EV/EBITDA9.029.028.7215.0411.30
P/B4.354.352.812.192.15
Growth & Yield
Revenue Growth8.8%8.8%19.0%8.3%—
EPS Growth180.0%180.0%162.5%-2415.7%—
Dividend Yield2.3%2.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

39.7%

muy exigente

EPS terminal req.

$0.04

Spread vs growth

140.3%

5Y implied EPS CAGR

27.0%

muy exigente

EPS terminal req.

$0.05

Spread vs growth

153.0%

10Y implied EPS CAGR

18.2%

exigente

EPS terminal req.

$0.07

Spread vs growth

161.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +55.9%

Total return

+55.9%

Start / end P/E

56.0x → 30.7x

EPS bridge

0.01 → 0.01

Residual

-81.3%

EPS growth+180.0%
Multiple rerating-45.2%
Dividend+2.3%
Residual / FX / buybacks / cross-term-81.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.